tofersen
Selected indexed studies
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (N Engl J Med, 2022) [PMID:36129998]
- Tofersen for SOD1 ALS. (Neurodegener Dis Manag, 2024) [PMID:39330700]
- Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. (Neurol Sci, 2025) [PMID:39820998]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tofersen for SOD1 ALS. (2024) pubmed
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (2022) pubmed
- Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (2020) pubmed
- Tofersen and other antisense oligonucleotides in ALS. (2025) pubmed
- Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. (2025) pubmed
- Tofersen. (2006) pubmed
- Tofersen: First Approval. (2023) pubmed
- Tofersen. (2012) pubmed
- Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations. (2025) pubmed
- Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. (2026) pubmed